Your browser is no longer supported. Please, upgrade your browser.
Aurinia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own7.24% Shs Outstand127.45M Perf Week-2.59%
Market Cap1.63B Forward P/E- EPS next Y-0.55 Insider Trans-0.35% Shs Float116.02M Perf Month-2.36%
Income- PEG- EPS next Q-0.14 Inst Own50.34% Short Float7.05% Perf Quarter-2.96%
Sales50.12M P/S32.55 EPS this Y-53.00% Inst Trans- Short Ratio1.75 Perf Half Y-17.31%
Book/sh3.22 P/B3.98 EPS next Y45.50% ROA- Target Price11.50 Perf Year-13.75%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range12.01 - 20.50 Perf YTD-7.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.56% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low6.58% ATR0.53
Employees294 Current Ratio- Sales Q/Q172417.20% Oper. Margin- RSI (14)43.24 Volatility2.40% 3.92%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.25 Prev Close12.96
ShortableYes LT Debt/Eq- EarningsFeb 24 AMC Payout- Avg Volume4.68M Price12.80
Recom1.70 SMA20-2.54% SMA50-10.91% SMA200-11.82% Volume1,154,219 Change-1.23%
Jan-25-21Reiterated H.C. Wainwright Buy $30 → $35
Nov-03-20Reiterated H.C. Wainwright Buy $34 → $28
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
Mar-16-18Reiterated Cantor Fitzgerald Overweight $14 → $16
Feb-08-18Initiated RBC Capital Mkts Outperform $9
Oct-30-17Reiterated H.C. Wainwright Buy $10 → $12
May-18-17Reiterated H.C. Wainwright Buy $12 → $10
Apr-11-17Initiated Cantor Fitzgerald Overweight $14
Mar-22-17Reiterated FBR & Co. Outperform $9 → $11
Dec-30-16Reiterated H.C. Wainwright Buy $10 → $8
Aug-17-16Reiterated H.C. Wainwright Buy $7 → $10
Jun-30-16Initiated H.C. Wainwright Buy $7
May-08-15Initiated MLV & Co Buy $9
Apr-08-21 07:38AM  
Mar-31-21 01:36AM  
Mar-15-21 08:52AM  
Mar-11-21 07:45AM  
Mar-02-21 06:05AM  
Feb-25-21 12:00AM  
Feb-24-21 04:02PM  
Feb-23-21 10:29AM  
Feb-18-21 06:05AM  
Feb-17-21 06:05AM  
Feb-14-21 02:08AM  
Feb-11-21 05:30PM  
Feb-01-21 07:45AM  
Jan-27-21 11:05AM  
Jan-26-21 08:07AM  
Jan-25-21 04:22PM  
Jan-22-21 08:24PM  
Jan-11-21 09:56AM  
Jan-08-21 06:05AM  
Jan-02-21 10:45AM  
Dec-30-20 11:08AM  
Dec-28-20 08:32AM  
Dec-21-20 03:40PM  
Dec-17-20 11:02AM  
Dec-16-20 07:15AM  
Dec-15-20 05:59PM  
Dec-02-20 06:05AM  
Nov-29-20 06:44AM  
Nov-20-20 05:00PM  
Nov-12-20 04:05PM  
Nov-11-20 08:45AM  
Nov-10-20 05:15PM  
Nov-09-20 04:05PM  
Nov-05-20 12:30PM  
Nov-04-20 02:25PM  
Nov-03-20 07:38AM  
Nov-02-20 04:05PM  
Oct-28-20 07:41AM  
Oct-27-20 04:05PM  
Oct-22-20 04:15PM  
Oct-16-20 06:28AM  
Oct-14-20 06:05AM  
Oct-05-20 01:30PM  
Oct-02-20 05:00PM  
Sep-29-20 06:44PM  
Sep-28-20 06:05AM  
Sep-16-20 03:26PM  
Sep-10-20 06:05AM  
Sep-04-20 06:04PM  
Aug-11-20 05:29PM  
Aug-04-20 12:30PM  
Jul-30-20 06:05AM  
Jul-28-20 12:33PM  
Jul-27-20 10:15AM  
Jul-23-20 06:59PM  
Jul-22-20 11:05PM  
Jul-21-20 05:27PM  
Jul-18-20 10:02AM  
Jul-15-20 01:15PM  
Jul-12-20 08:15PM  
Jun-22-20 06:05AM  
Jun-09-20 10:20AM  
Jun-08-20 03:00AM  
Jun-05-20 07:05AM  
Jun-04-20 06:34AM  
Jun-03-20 06:05AM  
Jun-01-20 04:05PM  
May-26-20 08:16AM  
May-20-20 10:04AM  
May-19-20 04:26PM  
May-15-20 04:05PM  
May-14-20 05:35PM  
May-07-20 06:05AM  
May-05-20 12:30PM  
Apr-29-20 01:12PM  
Apr-27-20 06:05AM  
Apr-21-20 07:33AM  
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Solomons NeilChief Medical OfficerMar 12Option Exercise3.0240,000120,800227,299Mar 15 04:36 PM
Solomons NeilChief Medical OfficerMar 12Sale13.4940,000539,600187,299Mar 15 04:36 PM
MILNE GEORGE M JRDirectorMar 05Buy13.005,00065,00045,000Mar 09 04:25 PM
Hayden Michael RDirectorJan 29Option Exercise5.7995,000550,10095,000Feb 02 03:18 PM
Leversage JillDirectorJan 29Buy16.034006,412400Feb 02 03:22 PM
Leversage JillDirectorJan 29Buy16.031,20019,2361,200Feb 02 03:22 PM
Robertson Stephen P.EVP, General CounselJan 28Buy16.1490014,5262,720Jan 29 12:24 PM